In Central Asia, Project HOPE is combating the burdens of tuberculosis, drug-resistant tuberculosis, and TB/HIV co-infection.
What's New in Central Asia
Cross-border TB Control
Representatives of Kazakhstan’s ministries and government agencies met with counterparts from Tajikistan and Kyrgyzstan to address Migration and Tuberculosis.
Project HOPE Announces Promising Study Outcomes in TB Adherence and…
Project HOPE announced promising results from a series of innovative studies aimed at improving Tuberculosis adherence, detection and prevention in patients in Kyrgyzstan, Kazakhstan and Malawi.
Media Training and Coverage of TB Among Working Migrants
A media training tour for journalists took place in October as part of the project “Addressing Cross-Border TB, M/XDR-TB and TB/AIDS Among Labor Migrants” implemented by Project HOPE Kazakhstan with the support of The Global Fund to Fight AIDS, Tuberculosis and Malaria.
Eliminating TB: A Collaborative Effort
The International Conference of Integrated TB Control in Almaty, Kazakhstan, brought together hundreds of TB experts and health care professionals.
The Global Fight Against a Potent Killer
A century-and-a-half ago tuberculosis (TB) was such a fact of daily life that the tragic romance of a young woman dying from the disease was immortalized in Giuseppe Verdi’s famous opera La Traviata. No one is writing operas, or their modern equivalent, movies or television shows about TB these days, and most people probably never give it a second thought — even though it is a disease that has afflicted the likes of celebrities like Nelson Mandela, Ringo Star, Sir Tom Jones and Tina Turner.
New Treatment Regimen Brings Hope for MDR-TB Patients
Hundreds of thousands of patients with multidrug resistant tuberculosis (MDR-TB), a form of TB infection caused by bacteria that are resistant to powerful drugs used to cure the disease, suddenly have reason to hope. The World Health Organization (WHO) has just cleared a new shortened treatment regimen for multidrug-resistant tuberculosis (MDR-TB) which carries grave risks for nearly half a million people who developed a condition that killed 190,000 people in 2014.